To explore the curative effect and safety of Risperidone，aripiprazole，sodium valproate，modified electroconvulsive therapy(MECT), or Magnetic seizure therapy(MST) with Clozapine in the treatment of treatment-resistant schizophrenia， and to provide the basis for clinical medication.
Age
18–60
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
The diagnosis of schizophrenia according to DSM-V
18～60 years old
2 prior failed treatment trials with 2 different antipsychotics at doses of at least 600 mg/day chlorpromazine equivalents, each of at least 6 weeks duration;
Signed an informed consent
You may not be if
patients to be diagnosed according to DSM-V for substance abused, development delayed
suffering from serious physical disease and can not accept the treatment
MST contraindications: intracranial metal substance, with heart pacemakers and cochlear implants, intracranial pressure
allergic to risperidone ,aripiprazole, or sodium valproate
Participated in any clinical subject within 30 days
